Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects (NCT07697560)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AH-008 Following Single Ascending Dose Administration in Healthy Subjects
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.
Who can join: Review the eligibility criteria below.
Location: ICON Clinial Research Unit — Salt Lake City, Utah
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- ICON Clinial Research Unit — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: +886 2 2786 2568
Email: yrwee@anhornmed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chemotherapy-induced Peripheral Neuropathy (CIPN)
Explore by condition: All Chemotherapy-induced Peripheral Neuropathy (CIPN) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.